ReNerve takes NervAlign into India as quarterly sales hit $584,000

ReNerve has converted Indian regulatory approval into its first commercial NervAlign Nerve Cuff procedure, with a Bangalore patient treated for an upper-extremity nerve repair. The milestone arrives after record quarterly sales of $584,000 and expands the company’s Asia-Pacific rollout.

  • First commercial NervAlign Nerve Cuff use in India
  • Bangalore procedure performed for an upper-extremity nerve repair
  • September-quarter sales reached a record $584,000
  • NetCentrix Ventures leading local commercialisation and distribution
  • Further Indian cases scheduled in the coming weeks
An image related to Renerve Limited A photo of the logo for Renerve Add us as a preferred source on Google
Image © middle. Logo © respective owner.

First Indian Procedure Converts Approval Into Use

Regulatory approval has now become operating-room use for ReNerve Limited (ASX:RNV). The company said the first Indian patient has received its FDA-cleared NervAlign Nerve Cuff in Bangalore during an upper-extremity nerve repair, marking the product’s first commercial use in the country.

The procedure follows India’s Central Drugs Standard Control Organisation marketing approval announced in August. ReNerve said the patient was recovering well, with no post-operative issues reported, and described feedback from the surgeon and patient as positive. That is an encouraging initial case, but it remains a single procedure rather than evidence of outcomes across a wider patient population.

NetCentrix Takes Local Commercialisation Forward

The Indian rollout is being conducted with NetCentrix Ventures, ReNerve’s commercialisation partner since April 2025. NetCentrix is providing local regulatory expertise and distribution networks, and has begun surgeon education and product in-servicing across India. ReNerve is supplying clinical and technical support, training and regulatory liaison, with further cases scheduled over the coming weeks.

India is the latest step in a regional sequence that has already included first Hong Kong and Malaysia surgeries, while ReNerve also holds marketing approval in Indonesia. The company says commercial activity now spans the United States, New Zealand, Hong Kong, Thailand, Malaysia, Indonesia, the Philippines and India, although the announcement does not break out revenue or case volumes by country.

Record Sales Raise the Commercial Stakes

The Indian case lands against a sharp acceleration in reported sales. ReNerve generated record September-quarter sales of $584,000, up 176% from the June quarter and 774% from the corresponding quarter a year earlier. The quarter also exceeded the company’s full-year FY26 sales of $510,357, while September became its first month above $200,000.

That trajectory gives the expansion a more important financial test: whether new approvals and distributor activity can translate into repeat procedures and sustained product revenue. The company cites India’s population of approximately 1.45 billion and a high incidence of road-trauma-related peripheral nerve injuries, alongside an estimated Indian nerve repair market of about US$700 million. Neither figure provides a forecast for ReNerve’s share of that market.

Next Milestones Extend Beyond the Nerve Cuff

ReNerve said it expects to provide further updates as Indian case volumes build and as it progresses commercial entry into Indonesia and the Philippines. It is also advancing the NervAlign Nerve Guide Matrix through Stage 3 of a four-stage development program, targeting completion by the end of calendar 2026, while scaling the NervAlign Nerve Conduit ahead of launch.

Get ASX:RNV news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

The Indian approval has produced a first commercial case; the more revealing test will be whether procedures, distributor activity and revenue build beyond the initial milestone.

Questions in the middle?

  • How quickly will Indian case volumes convert into disclosed sales?
  • Can NetCentrix establish repeat surgeon and hospital adoption beyond the first Bangalore procedure?
  • Will progress in India coincide with commercial entry into Indonesia and the Philippines before the end of the year?

Sources

1